Anti-NK1.1 Mouse Monoclonal Antibody (Clone PK136)

SK 787

Antigen:                                      Mouse NK1.1 (CD161, NKR-P1C, Ly-55)
Clone Name:                             PK136
Isotype:                                       Mouse IgG2a (Kappa Light Chain)
Application(s)*:                       Flow Cytometry, Immunoprecipitation, Immunohistochemistry, Immunofluorescence
Reactivity*:                                Mouse

* As reported in the literature and other commercial supplier websites


Clone PK136 recognizes mouse NK1.1, a cell surface antigen expressed by natural killer cells and a subset of T cells in the NK1.1 mouse strains including CE, C57BL/6, FVB/N, and NZB. NK1.1 is not expressed by NK cells from the following mouse strains: 129, A, AKR, BALB/c, C3H, CBA, and SJL.


This antibody was derived in 1984 by injection of splenocytes (enriched for NK-1-positive cells) and bone marrow cells from CE mice into (C3H x BALB/c) F1 mice. Splenocytes from these mice were then fused with Sp2/0-Ag14 cells to generate hybridomas.


  • Gloria C. Koo, PhD, formerly at Memorial Sloan Kettering
  • JoAnne R. Peppard, formerly at Memorial Sloan Kettering

Key References

  • Koo GC and Peppard JR (1984) Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma 3: 301-303 (PubMed ID: 6500587)
  • Koo GC et al. (1986) The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. Journal of Immunology. 137: 3742-3747 (PubMed ID: 3782794)
  • Reichlin A and Yokoyama WM (1998) Natural killer cell proliferation induced by anti-NK1.1 and IL-2. Immunology and Cell Biology 76: 143-152 (PubMed ID: 9619484)
  • Kung SK et al. (1999) The NKR-P1B gene product is an inhibitory receptor on SJL/J NK cells. Journal of Immunology 162: 5876-5887 (PubMed ID: 10229823)

Licensing Information

This hybridoma may be licensed nonexclusively for commercial purposes. For more information, please contact

Additional Information

Purified antibody may be available for sale through the Memorial Sloan Kettering Antibody & Bioresource Core Facility. Please email for further information.

Stage of Development

Ready to use